News – Page 942 – Endpoints News

Analyst call with Allergan execs stokes anticipation of a plan to split the company in ‘a month or two’

6 years ago

Sanofi's John Reed continues to reorganize R&D, cutting 466 jobs while boosting cancer, gene therapy research

6 years ago

Arcturus expands collaboration, adding $30M cash; Kura shoots for $100M raise

6 years ago

Chicago biotech argues bluebird, Third Rock 'killed' its rival, pioneering thalassemia gene therapy in lawsuit

6 years ago

Woodford braces political storm as UK financial regulators scrutinize fund suspension

6 years ago

New study questions the need for 12 years of market exclusivity for biologics

6 years ago

Gilead baits new alliance with $45M upfront, diving into the busy protein degradation field

6 years ago

A new number 1 drug? Keytruda tapped to top the 10 biggest blockbusters on the world stage by 2024

6 years ago

Ironwood, Allergan add a slate of PhIIIb data to its Linzess pitch for physicians, patients

6 years ago

Investor day prep at Merck includes a new strategy to pick up the pace on M&A — report

6 years ago

Bob Langer's first port of call — Polaris Partners — maps $400M for ninth fund

6 years ago

'It's a growth play': Catalent acquires Bristol-Myers' European launch pad, expanding global CDMO ops

6 years ago

Preclinical antisense biotech, led by former Sarepta CEO Kaye, vaults on to Nasdaq with upsized IPO

6 years ago

David de Graaf now has his $28.5M launch round in place, building a coenzyme A platform in his latest startup

6 years ago

Unity's early longevity data look 'encouraging'; Adaptive Biotechnologies looks to raise $200M in IPO

7 years ago

Study: Just half of postmarketing commitment trials are published

7 years ago

Right back at you, Pfizer: BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor that could ...

7 years ago

Stepping on Roche's toes, Merck cuts into SCLC niche with third-line Keytruda OK

7 years ago

Sanofi aligns itself with Google to streamline drug development

7 years ago

After watching its share price soar on a Bloomberg report and heated rumors, Biohaven stock takes a billion-dollar ...

7 years ago

Roche fields first approval for Rozlytrek in the run-up to a showdown with Bayer, Pfizer

7 years ago

The top 10 blockbuster drugs in the late-stage pipeline — Evaluate adds 6 new therapies to heavy-hitter list

7 years ago

AstraZeneca/Merck win EU approval for frontline maintenance treatment of ovarian cancer, months after FDA endorsement

7 years ago

AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug

7 years ago

First page Previous page 939 940 941942943 944 945 Next page Last page